Please assess the completion status of the following clinical trial:

Trial Title: Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male/Female patients aged 18 years or over~* Patients must provide written informed consent~* Part I: Patients with histologically confirmed, locally advanced or metastatic solid tumors. Part II and Part III: Patients with histologically confirmed, pancreatic adenocarcinoma for which the established therapy is Abraxane®/Gemcitabine (clinical standard of care)~* Life expectancy above 3 months~* Patients willing to comply with treatment follow-up~* ECOG Performance status 0 or 1~* Adequate baseline organ function (hematologic, liver, renal and nutritional)~* Use a reliable method of contraception in fertile men and women~Exclusion Criteria:~* Active infection or other serious illness or autoimmune disease~* Treatment with live attenuated vaccines in the last three weeks~* Known chronic liver disease (liver cirrhosis, chronic hepatitis)~* Treatment with another investigational agent within its five half-lives prior to VCN-01 infusion~* Viral syndrome diagnosed during the two weeks before inclusion~* Chronic immunosuppressive therapy~* Concurrent malignant hematologic or solid disease~* Pregnancy or lactation. Patients must agree to use effective contraception or be surgically sterile.~* Patients receiving full-dose anticoagulant / antiplatelet therapy~* Adequate levels of neutralizing antibodies against adenovirus~* Patients with Li Fraumeni syndrome or with previous known retinoblastoma protein pathway germinal deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part I: Dose Escalation, Single Agent (Type: EXPERIMENTAL): Single intravenous injection of VCN-01 oncolytic adenovirus
- Part II: Dose Escalation, Combination (Type: EXPERIMENTAL): Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
- Part III: Dose Escalation, Combination, delayed schedule (Type: EXPERIMENTAL): Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).